MK-677 (Ibutamoren): The Oral Secretagogue

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/mk-677-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol.

Overview

MK-677 — also known as Ibutamoren — is one of the few growth-hormone-related compounds in the optimization toolkit that does not require a needle. It is a non-peptide, orally bioavailable ghrelin receptor agonist that mimics the action of the hunger hormone ghrelin to stimulate the body's own pulsatile release of growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1).

Despite the "secretagogue" label it shares with injectable peptides like CJC-1295 and ipamorelin, MK-677 is technically a small molecule, not a peptide. That distinction matters for the chemistry, the regulatory framing, and how the compound behaves in the body.

Who it tends to interest:

• Optimizers who want the metabolic profile of GH-axis support without daily injections
• Athletes and lifters looking for deeper sleep and improved recovery (note: banned by WADA)
• Adults exploring lean-mass preservation, skin quality, and recovery in their 30s, 40s, and beyond
• Anyone curious about a 24-hour-coverage option versus the short half-life of injectable secretagogues

TL;DR:

• Oral, once-daily, non-peptide
• Elevates GH and IGF-1 for roughly 24 hours per dose
• Typical range: 10–25 mg/day, often dosed at night
• Common effects: increased appetite, deeper sleep, mild water retention
• NOT FDA-approved. Sold as a research chemical. Banned by WADA.

Mechanism of Action

MK-677 binds and activates the growth hormone secretagogue receptor 1a (GHSR-1a) — the same receptor targeted by endogenous ghrelin. This is the receptor injectable peptides like ipamorelin, hexarelin, and GHRP-2/6 also act on. The result is a stimulated release of GH from the anterior pituitary.

Key pharmacological features:

1. Pulsatile preservation — Unlike exogenous recombinant HGH, MK-677 prompts the body to release its own GH in pulses, preserving natural feedback architecture.
2. 24-hour pharmacokinetics — Plasma half-life of roughly 4–6 hours, but the downstream GH/IGF-1 elevation persists across a full 24-hour cycle with daily dosing.
3. IGF-1 elevation — Studies indicate sustained increases in IGF-1 of 40–90% over baseline at therapeutic doses, typically plateauing by week 4–8.
4. Non-peptide structure — Resistant to gastric breakdown, which is what makes oral administration viable in the first place.
5. Ghrelin mimicry — Because GHSR-1a is the ghrelin receptor, MK-677 also drives the appetite and gastric motility effects you'd expect from ghrelin itself.

Peer-reviewed research (notably the Murphy and Sigalos lines of work on GH secretagogues) suggests MK-677 produces GH/IGF-1 profiles broadly comparable to younger physiological levels in older adults — without the cost or kinetics of injectable GH.

Dosing Protocols

MK-677 is typically supplied as a liquid (in PEG or alcohol solution) or as capsules. Oral bioavailability is reasonable for a small molecule, and dosing once daily is sufficient given the long downstream effect.

Dosage Tiers

Doses above 25 mg/day are not generally associated with proportional benefit in available research and tend to amplify side effects (especially water retention and lethargy).

Timing: Morning vs. Night

There is an ongoing debate in the community, and reasonable arguments on both sides:

• Night dosing (most common): Aligns the GH pulse with natural nocturnal release, often enhances slow-wave sleep, and lets you "sleep through" the appetite spike. Downside: some users report grogginess on waking.
• Morning dosing: Avoids any sleep-disturbance risk and pushes appetite into daylight hours when food intake is more practical. Downside: may mute natural nighttime GH pulse.
• Split dosing (less common): 5–10 mg twice daily for users sensitive to peak effects.

Oral Bioavailability Notes

• Take consistently — at the same time each day — to maintain stable IGF-1 levels.
• Food does not dramatically impair absorption, but a low-fat window may improve consistency.
• The liquid form is easy to underdose or overdose if not measured carefully; use a calibrated oral syringe.

Expected Outcomes

Realistic expectations matter. MK-677 is not HGH and won't produce the same magnitude of effect, but research and user-reported data suggest a fairly predictable arc.

Week 1–2: Appetite and Initial Adaptation

• Marked increase in hunger (the ghrelin mimicry shows up first)
• Possible mild water retention in hands, feet, or face
• Some users notice immediate sleep changes

Week 4–8: Sleep and Recovery

• Deeper, more restorative sleep — particularly slow-wave sleep
• Faster recovery between workouts
• Improved skin texture and hair quality reported anecdotally
• IGF-1 typically reaches new steady state

Week 8–12: Body Composition

• Lean mass increases reported, particularly when paired with resistance training and adequate protein
• Fat distribution may shift; body composition outcomes depend heavily on caloric context
• Joint comfort and connective tissue resilience often improved

IGF-1 Changes

Expect IGF-1 to rise 40–90% above baseline at standard doses. This is the primary biomarker for confirming the compound is working as intended — and the primary safety signal to keep an eye on.

Side Effects & Safety

MK-677's side-effect profile is well-characterized in the research literature and consistent across user reports.

Common Side Effects

• Increased appetite — Sometimes dramatically. The biggest "lifestyle" factor with this compound.
• Water retention — Mild to moderate; typically subsides over the first 2–4 weeks but doesn't always fully resolve.
• Lethargy / morning grogginess — Especially with night dosing or higher doses.
• Tingling or numbness in extremities — Mild peripheral neuropathy-like sensations have been reported; usually transient.
• Vivid dreams — Often noted alongside deeper sleep.

Metabolic Considerations

• Insulin sensitivity — Research indicates MK-677 can decrease insulin sensitivity and elevate fasting glucose, particularly at higher doses or with prolonged use. This is a real concern, not a footnote.
• Prolactin — Modest increases reported. Generally not clinically significant but worth tracking if symptoms appear.
• Cortisol — Minimal impact at standard doses (one of MK-677's advantages over older secretagogues like GHRP-6).

Contraindications

Do not use MK-677 if you have:

• Diabetes or prediabetes — Glucose-handling effects are a meaningful risk.
• Congestive heart failure (CHF) — Fluid retention is dangerous in this population. Older trials in CHF patients were halted for this reason.
• Active cancer — IGF-1 elevation raises theoretical concerns.
• Pregnancy or breastfeeding — Not studied.
• A history of significant hormonal cancers (theoretical concern with IGF-1)

Regulatory Status

• Not FDA-approved for any human use
• Sold as a research chemical in the United States
• Banned by WADA for tested athletes — competitive lifters, runners, and combat athletes should not use it during a sanctioned career
• Legality varies by jurisdiction; always check local rules

Stacking

MK-677 stacks logically with other GH-axis tools, but a few combinations are smarter than others.

MK-677 + CJC-1295 / Ipamorelin (Pulsatile Layering)

The most discussed stack. MK-677 provides 24-hour baseline elevation while CJC-1295/ipamorelin produces sharper, cleaner pulses. The pairing can yield a more physiological GH pattern than either alone.

• MK-677: 10–15 mg/day (often lowered when stacking)
• CJC-1295 (no DAC) + ipamorelin: standard dosing, 1–3x daily
• Useful for users who want both depth (MK-677) and pulse architecture (injectable)

MK-677 + BPC-157 (Recovery / Joint Support)

A favorite among athletes returning from injury or training heavy.

• MK-677: standard dose
• BPC-157: 250–500 mcg/day
• Rationale: MK-677's connective tissue and IGF-1 benefits pair well with BPC-157's healing profile

MK-677 + Testosterone Replacement (Under Medical Supervision)

For men on TRT, MK-677 can complement the recovery and body composition outcomes — but this is firmly in "discuss with your prescriber" territory.

Stacks to Approach Carefully

• MK-677 + exogenous HGH — Redundant and amplifies side effects; not recommended without clinical oversight
• MK-677 + high-dose insulin or aggressive bulks — Stacks the glucose risk
• MK-677 + other ghrelin agonists (hexarelin, GHRP-6) — Redundant receptor activity, more side effects, no additional benefit

Cycling

This is one of the more nuanced questions with MK-677, and the honest answer is: the evidence is mixed.

The Case for Continuous Use

• GHSR-1a receptor desensitization with chronic MK-677 use appears minimal in available studies
• IGF-1 elevation has been shown to persist over 12+ months of continuous dosing in research
• Some clinicians treat it as a long-term metabolic intervention rather than a cycle

The Case for Cycling

• Long-term glucose and insulin sensitivity changes are a real consideration
• Down-cycles allow appetite and water retention to normalize
• Periodic bloodwork is easier to interpret against a clean baseline
• Psychological "reset" — a break helps distinguish the compound's effects from baseline

Common Cycle Structures

A reasonable default for someone new to the compound: 12 weeks on, 4 weeks off, with bloodwork at baseline, week 8, and end-of-cycle.

Bloodwork to Monitor

Bloodwork is non-negotiable on MK-677. The compound's effects are systemic and the safety signals show up in labs before they show up in symptoms.

Baseline (Before Starting)

• IGF-1 — Your reference point. Most adults sit in the 100–250 ng/mL range depending on age.
• Fasting glucose
• HbA1c (A1c) — 3-month glucose average
• Fasting insulin (optional but useful)
• Prolactin
• Complete metabolic panel (CMP)
• Lipid panel

On-Cycle (Week 8 and End)

• IGF-1 — Expect 40–90% above baseline. If you're well above the upper reference range, consider dose reduction.
• Fasting glucose and A1c — The most important safety signals. Trending upward is a reason to reassess.
• Prolactin — Modest increases are normal; large jumps warrant investigation.
• CMP — Particularly liver and kidney markers

Watch For

• A1c creeping above 5.7%
• Fasting glucose consistently above 100 mg/dL
• IGF-1 significantly above the age-adjusted reference range
• Symptomatic edema or rapid weight gain that isn't lean tissue

Frequently Asked Questions

Q: Is MK-677 legal? A: In the U.S., MK-677 is sold as a research chemical. It is not FDA-approved for human use, not scheduled as a controlled substance, but also not legal to market for human consumption. It is banned by WADA for tested athletes. Legality varies internationally — check your jurisdiction.

Q: Will I gain fat on MK-677? A: Not inherently. The compound increases appetite significantly, so weight gain depends almost entirely on whether you respect your caloric targets. Some early weight gain is water retention, not fat. Research suggests lean mass tends to increase when dosing is paired with training and adequate protein.

Q: Does MK-677 shut down natural GH production? A: Available research does not show meaningful suppression of the body's own GH axis. Because MK-677 works by stimulating the pituitary rather than replacing GH, the feedback architecture remains intact. This is one of its key advantages over exogenous HGH.

Q: Should I take MK-677 with food? A: It can be taken with or without food. Some users report better absorption on an empty stomach, but consistency matters more than timing relative to meals. Pick a routine and stick to it.

Q: How long until I notice anything? A: Appetite changes are often immediate (within days). Sleep changes typically show up in weeks 2–4. Body composition changes are a 8–12 week story. IGF-1 confirmation comes via bloodwork.

Q: Can women take MK-677? A: Yes, and women often respond well at lower doses (10 mg or even 5–7.5 mg). The hormonal effects (prolactin, etc.) are worth monitoring, and pregnancy/breastfeeding are clear contraindications.

Q: Does MK-677 cause cancer? A: There is no direct evidence that MK-677 causes cancer. The theoretical concern stems from sustained IGF-1 elevation, which is associated in epidemiology with certain cancer risks at extreme levels. Users with a personal or strong family history of hormonally-driven cancers should discuss this with a clinician before starting.

Q: What happens when I stop taking MK-677? A: Effects taper off as the compound clears. Appetite typically normalizes within a week. Water retention drops in the first 1–2 weeks. IGF-1 returns toward baseline over several weeks. Lean mass gains can be retained with continued training and nutrition.

Related Content

• CJC-1295 Protocol Guide
• Ipamorelin Protocol Guide
• GH Peptide Stacking Guide
• Bloodwork Checklist
• FDA Status Guide

Disclaimer: This content is for educational purposes only and is not medical advice. MK-677 (Ibutamoren) is a research compound and is not FDA-approved for human use. It is banned by the World Anti-Doping Agency. Consult a licensed healthcare provider before starting any peptide or secretagogue protocol.

Source: https://peptides.nyc/learn/mk-677-protocol